Test Bank For Pharmacology for Canadian Health Care Practice 3rd Edition By Linda Lane Lilley Ph.D. RN

Test Bank For Pharmacology for Canadian Health Care Practice 3rd Edition By Linda Lane Lilley Ph.D. RN

Chapter 03: Legal and Ethical ConsiderationsLilley: Pharmacology for Canadian Health Care Practice, the 3rd Canadian Edition MULTIPLE CHOICE1. In the development of a new drug by a pharmaceutical company, the researcher must ensure that the participants in experimental drug studies do not have unrealistic expectations of the new drug’s usefulness. What will the researcher include in the design of the study to prevent bias that may occur?a.A placebob.Health Canada approvalc.Informed consentd.Efficacy information ANS: ATo prevent bias that may occur as a result of unrealistic expectations of an investigational new drug, a placebo will be incorporated into the study. Health Canada approval, if given, does not be obtained until after phase III of the study. Informed consent is required in all drug studies. Efficacy information is not determined until the study is underway. DIF: Cognitive Level: Comprehension REF: pp. 52-53 2. A member of an investigational drug study team is working with healthy volunteers whose participation will help determine the optimal dosage range and pharmacokinetics of the drug. In what type of study is the team member participating?a.Phase Ib.Phase IIc.Phase IIId.Phase IV  ANS: APhase I studies involve small numbers of healthy volunteers to determine the optimal dosage range and the pharmacokinetics of the drug. Phases II, III, and IV involve progressively larger numbers of volunteers who have the disease or ailment that the drug is designed to diagnose or treat. DIF: Cognitive Level: Application REF: pp. 52-53 3. A patient has a prescription for a drug classified as Schedule F. What important information should the nurse give this patient about obtaining refills for this medication?a.No prescription refills are permitted.b.Refills may be obtained via telephone order.c.Refills are indicated by the prescriber.d.The patient may have no more than six refills in a 12-month period.  ANS: CSchedule F contains a list of drugs that can be sold and refilled only on prescription; prescriptions can be refilled as often as indicated by the prescriber. DIF: Cognitive Level: Analysis REF: p. 49 4. A patient has been chosen to be a recipient of an investigational drug for heart failure and has given informed consent. Which is indicated by the patient’s informed consent?a.The patient has been informed of the possible benefits of the new therapy.b.The patient will be informed of the details of the study as the research continues.c.The patient will not be assured of receiving the actual drug during the experiment.d.The patient has received an explanation of the study’s purpose, procedures, and the benefits and risks involved.  ANS: DInformed consent involves the careful explanation of the purpose of the study, procedures to be used, and the possible benefits and risks involved. Being informed of the possible benefits of the new therapy, being informed of the study details as research continues, and being assured of receiving the actual drug during the experiment do not describe informed consent. DIF: Cognitive Level: Comprehension REF: p. 52 5. Which is the most significant part of legislation in regard to professional nursing practice?a.Canada Health Actb.Nursing Practice Actc.Controlled Drugs and Substances Actd.Personal Information Protection and Electronic Documents Act  ANS: BNurse practice acts (NPAs) are regulatory laws that are instrumental in defining the scope of nursing practice and that protect public health, safety, and welfare. Nursing practice in Canada is regulated by separate acts in each of the 10 provinces and 3 territories. These acts grant self-governance to the nursing profession, direct entry into nursing practice, define the scopes of practice, and identify disciplinary actions. NPAs are the most significant part of legislation in regard to professional nursing practice. DIF: Cognitive Level: Comprehension REF: p. 54 6. What potential failure is identified when a patient with a documented penicillin allergy receives 1.2 g of benzylpenicillin IV?a.Failure to assessb.Failure to evaluatec.Failure to ensure safetyd.Failure to identify the patient  ANS: CFailure to ensure safety includes lack of adequate monitoring, failure to identify patient allergies and other risk factors related to medication therapy, inappropriate drug administration technique, and failure to implement appropriate nursing actions because of improper assessment of the patient’s condition. Whereas failure to assess or evaluate includes failure to see significant changes in the patient’s condition after taking a medication, failure to report these changes, failure to take a complete medication history and nursing assessment/history, and failure to monitor the patient after medication administration. Failure to identify the patient’s identity is a medication error. DIF: Cognitive Level: Application REF: p. 55 7. Which statement correctly describes drugs in Part G, Part II of the Food and Drugs Act?a.They are drugs with high potential for misuse that have an accepted medical use.b.They are drugs with high potential for misuse that do not have an accepted medical use.c.They are medically accepted drugs that may cause mild physical or psychological dependence.d.They are medically accepted drugs with very limited potential for causing mild physical or psychological dependence.  ANS: APart G, Part II drugs are those with high potential for misuse that have an accepted medical use (e.g., barbiturates). DIF: Cognitive Level: Comprehension REF: p. 50 8. Which contributes to drug polymorphism?a.The number of drugs ordered by the physicianb.The patient’s drug historyc.The patient’s age, sex, and body compositiond.Different dosage forms of the same drug  ANS: CA patient’s age, sex, size, and body composition are some of the factors that contribute to drug polymorphism, which is the effect of such variables on how an individual absorbs or metabolizes specific drugs. The number of drugs ordered by the physician, the patient’s drug history, and different dosage forms of the same drug are not factors that contribute to drug polymorphism. DIF: Cognitive Level: Comprehension REF: p. 48 9. Which best describes drug polymorphism?a.Cultural and genetic effects on drug metabolism and excretionb.Gender and cultural effects on drug absorption and distributionc.Age or body composition effects on drug absorption or metabolismd.Multidrug use resulting in impaired excretion  ANS: CDrug polymorphism is the variation in response to a drug because of a patient’s age, sex, size, and body composition. DIF: Cognitive Level: Comprehension REF: p. 48